Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Short Interest Up 6.0% in December

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) was the target of a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 149,700 shares, a growth of 6.0% from the November 30th total of 141,200 shares. Based on an average daily volume of 16,500 shares, the short-interest ratio is currently 9.1 days. Approximately 0.5% of the company’s shares are sold short.

Wall Street Analyst Weigh In

EPRX has been the subject of several analyst reports. Rodman & Renshaw started coverage on Eupraxia Pharmaceuticals in a research report on Thursday, November 14th. They set a “buy” rating and a $9.00 target price for the company. RODMAN&RENSHAW upgraded Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, November 14th.

Eupraxia Pharmaceuticals Stock Up 2.6 %

EPRX opened at $3.17 on Wednesday. Eupraxia Pharmaceuticals has a twelve month low of $2.20 and a twelve month high of $5.58. The company has a fifty day moving average of $3.12 and a 200-day moving average of $2.78. The stock has a market cap of $86.48 million and a PE ratio of -4.40.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.